论文部分内容阅读
目的观察依达拉奉联合降纤酶治疗急性脑梗死的临床疗效及安全性。方法将80例急性脑梗死患者随机分为两组,分别采用单用降纤酶及依达拉奉联合降纤酶治疗,以疗程14 d临床疗效、治疗前后神经功能缺损程度评分(CSS)、血浆纤维蛋白原(Fg)含量变化观察疗效。结果两组患者疗程14 d观察显示,治疗组总有效率90.0%,明显高于对照组(70.0%),差异有统计学意义(P<0.05)。治疗前后神经功能缺损评分,治疗组与对照组比较,差异有统计学意义(P<0.05)。两组Fg水平较治疗前明显降低(P<0.01),且未见明显不良反应。结论依达拉奉联合降纤酶治疗急性脑梗死安全有效,能显著改善患者的预后。
Objective To observe the clinical efficacy and safety of edaravone combined with defibrase in the treatment of acute cerebral infarction. Methods Eighty patients with acute cerebral infarction were randomly divided into two groups. The patients were treated with defibrase and edaravone combined with defibrase alone. The therapeutic effect was 14 days after treatment. The scores of neurological deficits (CSS) before and after treatment, Plasma Fibrinogen (Fg) content changes observed effect. Results The 14-day course of treatment showed that the total effective rate was 90.0% in the treatment group, which was significantly higher than that in the control group (70.0%), the difference was statistically significant (P <0.05). Before and after treatment, neurological deficit score, the treatment group compared with the control group, the difference was statistically significant (P <0.05). Fg levels in both groups were significantly lower than before treatment (P <0.01), and no obvious adverse reactions. Conclusion Edaravone combined with defibrase in the treatment of acute cerebral infarction is safe and effective, which can significantly improve the prognosis of patients.